Vaccine trials to hold in Nigeria in February

The trials were expected to commence earlier but were postponed after national regulators expressed the need to gather more information.

The second phase of GlaxoSmithKline's experimental Ebola vaccine trials have been slated to begin in February 2015 and will hold in Nigeria, Cameroon, Ghana, Mali and Senegal.

A two-day meeting of the national regulatory authorities and ethics committees was hosted earlier this week by the World Health Organization (WHO) after which the UN agency stated that all aspects of the proposed trials had been thoroughly discussed.

“Reviewing countries requested additional documentation from the manufacturer of the vaccine, GlaxoSmithKline, before authorization of the trials,” the WHO said in a statement.

“If these steps are completed to the satisfaction of the national authorities, Phase II trials are likely to begin in February,” the statement added.

GSK’s vaccine is currently in the first phase of clinical trials and its suitability for use in humans is being tested in Switzerland, Britain, Mali and the United States.


Eyewitness? Submit your stories now via social or:


Recommended articles

Senate confirms Yahaya as Chief of Army Staff

KASU asks parents to sign undertaking that their children will be of good behaviour

A University student who criticized Akwa Ibom Governor on Facebook has been expelled

APC slams Gov Obaseki over demolition of private properties in Edo

Bill to regulate human organs harvest scales 2nd reading in Lagos Assembly

Festus Keyamo says Twitter must be regulated in Nigeria

ICPC calls for strict law enforcement to tackle corruption

Akeredolu to establish business district in Akure to boost economic activities

Moghalu elected into board of UN group